Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: MCR141
MIFTS: 48

Mucormycosis

Categories: Infectious diseases, Neuronal diseases, Oral diseases, Rare diseases, Respiratory diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Mucormycosis

About this section

MalaCards integrated aliases for Mucormycosis:

Name: Mucormycosis 12 75 53 59 3 15 17
Zygomycosis 12 75 53 59 3 33
Disseminated Mucormycosis 12 33

Characteristics:

Orphanet epidemiological data:

59
zygomycosis
Inheritance: Not applicable; Age of onset: All ages;

Classifications:

MalaCards categories:
Global: Rare diseases Infectious diseases
Anatomical: Respiratory diseases Oral diseases Neuronal diseases
See all MalaCards categories (disease lists)
ICD10: 33 34
Orphanet: 59  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:8485
MESH via Orphanet 45 D009091 D020096
UMLS via Orphanet 73 C0026718 C0043541
Orphanet 59 ORPHA73263
Sources

Summaries for Mucormycosis

About this section
CDC : 3 Mucormycosis (sometimes called zygomycosis) is a serious but rare fungal infection caused by a group of molds called mucormycetes. These fungi live throughout the environment, particularly in soil and in decaying organic matter, such as leaves, compost piles, or rotten wood.1 People get mucormycosis by coming in contact with the fungal spores in the environment. For example, the lung or sinus forms of the infection can occur after someone breathes in spores. These forms of mucormycosis usually occur in people who have health problems or take medicines that lower the body's ability to fight germs and sickness.3,6 Mucormycosis can also develop on the skin after the fungus enters the skin through a cut, scrape, burn, or other type of skin trauma.

MalaCards based summary : Mucormycosis, also known as zygomycosis, is related to aspergillosis and carotid artery thrombosis. An important gene associated with Mucormycosis is HSPA5 (Heat Shock Protein Family A (Hsp70) Member 5), and among its related pathways/superpathways are Salmonella infection (KEGG) and Glucocorticoid receptor regulatory network. The drugs Miconazole and Voriconazole have been mentioned in the context of this disorder. Affiliated tissues include brain, sinuses and lungs of immunocompromised people.

Disease Ontology : 12 An opportunistic mycosis that results in fungal infection located in sinuses, located in brain, or located in lungs of immunocompromised people, has material basis in Mucorales molds.

Wikipedia : 75 Mucormycosis is any fungal infection caused by fungi in the order Mucorales. Generally, species in the... more...

Sources

Related Diseases for Mucormycosis

About this section

Diseases related to Mucormycosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 498)
# Related Disease Score Top Affiliating Genes
1 aspergillosis 31.1 IFNG CSF2
2 carotid artery thrombosis 30.8 IFNG CSF2
3 ethmoid sinusitis 30.6 RHNO1 CSF2
4 candidiasis 30.1 IFNG CARD9
5 cryptococcosis 29.9 IFNG CARD9
6 acquired immunodeficiency syndrome 29.9 IFNG CSF2
7 paranasal sinus disease 29.8 RHNO1 IFNG
8 opportunistic mycosis 29.5 RHNO1 IFNG CARD9
9 neutropenia 10.7
10 diabetes mellitus, ketosis-prone 10.6
11 lymphocytic leukemia 10.6
12 leukemia, acute lymphoblastic 10.5
13 cellulitis 10.5
14 kearns-sayre syndrome 10.4
15 diabetes mellitus 10.4
16 leukemia, acute myeloid 10.4
17 acute leukemia 10.4
18 large granular lymphocyte leukemia 10.4 IFNG CSF2
19 trichosporonosis 10.4 IFNG CSF2
20 candida glabrata 10.4 IFNG CSF2
21 exophthalmos 10.4
22 human t-cell leukemia virus type 2 10.4 IFNG CSF2
23 myeloid leukemia 10.4
24 yemenite deaf-blind hypopigmentation syndrome 10.4
25 invasive aspergillosis 10.4
26 osteomyelitis 10.4
27 hard palate cancer 10.4
28 meconium aspiration syndrome 10.3 IFNG CSF2
29 leukemia 10.3
30 cyclic neutropenia 10.3 IFNG CSF2
31 cytomegalovirus retinitis 10.3 IFNG CSF2
32 kidney disease 10.3
33 cryptococcal meningitis 10.3 IFNG CSF2
34 hemosiderosis 10.3
35 toxic shock syndrome 10.3
36 peritonitis 10.3
37 rare hereditary hemochromatosis 10.3
38 hematopoietic stem cell transplantation 10.3
39 ptosis 10.3
40 cavernous sinus thrombosis 10.3
41 myelodysplastic syndrome 10.3
42 smallpox 10.3 IFNG CSF2
43 enterocolitis 10.3
44 thrombosis 10.3
45 respiratory failure 10.3
46 langerhans cell histiocytosis 10.2 IFNG CSF2
47 headache 10.2
48 hemiplegia 10.2
49 acute kidney failure 10.2
50 perinatal necrotizing enterocolitis 10.2

Graphical network of the top 20 diseases related to Mucormycosis:



Diseases related to Mucormycosis
Sources

Symptoms & Phenotypes for Mucormycosis

About this section
Sources

Drugs & Therapeutics for Mucormycosis

About this section

Drugs for Mucormycosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 25)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Voriconazole Approved, Investigational Phase 4 137234-62-9 71616
3 Antifungal Agents Phase 4
4 Anti-Infective Agents Phase 4
5 14-alpha Demethylase Inhibitors Phase 4
6 Cytochrome P-450 CYP3A Inhibitors Phase 4
7 Cytochrome P-450 Enzyme Inhibitors Phase 4
8 Steroid Synthesis Inhibitors Phase 4
9 Hormones Phase 4
10 Hormone Antagonists Phase 4
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4
12
Isavuconazole Approved, Investigational Phase 3 241479-67-4
13
Amphotericin B Approved, Investigational Phase 2 1397-89-3 14956 5280965
14
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
15
Iron Approved, Experimental Phase 2 15438-31-0, 7439-89-6 23925 27284
16
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
17 Liposomal amphotericin B Phase 2
18 Chelating Agents Phase 2
19 Anti-Bacterial Agents Phase 2
20 Iron Chelating Agents Phase 2
21 Antiparasitic Agents Phase 2
22 Antiprotozoal Agents Phase 2
23 Nutrients Phase 2
24 Micronutrients Phase 2
25 Trace Elements Phase 2

Interventional clinical trials:

(show all 15)
# Name Status NCT ID Phase Drugs
1 A Prospective, Randomized Trial Comparing the Efficacy and Safety of Voriconazole Administered With Therapeutic Drug Monitoring vs. Standard Dosing Completed NCT01416025 Phase 4 Prospective TDM Arm
2 A Phase 3, Multi-center, Open Label Study to Evaluate Safety and Efficacy of AK1820 for Treatment of Adult Japanese Patients With Deep Mycosis Recruiting NCT03471988 Phase 3 AK1820;Voriconazole
3 Treatment of Rhino-Sinusal Mucormycosis Through Transnasal Endoscopic Surgery Extended to the Skull Base. Unknown status NCT02226705 Phase 2
4 The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) Study Completed NCT00419770 Phase 2 deferasirox;Placebo;Liposomal amphotericin B
5 AMBIZYGO: Efficacy of High Dose [10 mg/kg/j] Liposomal Amphotericin B (Ambisome)Efficacy in Initial Zygomycosis Treatment:Phase II Trial Completed NCT00467883 Phase 2 Liposomal Amphotericin B
6 Phase II Study of Safety, Tolerance, Efficacy, and Pharmacokinetics of Posaconazole (SCH 56592) for the Treatment of Invasive Fungal Infections in Immunocompromised Hosts Completed NCT00034671 Phase 2 Posaconazole oral suspension
7 A Phase II Trial of the Safety and Efficacy of Iron Reduction by Phlebotomy in Recipients of Hematopoietic Stem Cell Transplants Completed NCT00689182 Phase 2
8 A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects Recruiting NCT03816176 Phase 2 Isavuconazonium sulfate
9 The Value of Real-Time Polymerase Chain Reaction (RT-PCR) Assay, Galactomannan and β-D-Glucan Detection (GM/G-Test) for Diagnosis of Invasive Fungal Infection (IFI) in Chinese Patients After Hematopoietic Stem Cell Transplantation (HSCT) Unknown status NCT00460330
10 Prospective Evaluation of a New Molecular Tool for Early Diagnosis of Mucormycosis Completed NCT02845934
11 Multicenter Observational Study on Epidemiology, Treatment and Outcome of Mucormycosis in India Completed NCT03429023
12 Early Molecular Detection for the Improved Diagnosis of Invasive Pulmonary Aspergillosis and Invasive Pulmonary Zygomycosis Completed NCT00923832
13 Invasive Mould Infections in Indian ICUs - Descriptive Epidemiology, Management and Outcome Completed NCT02683642
14 Mucormycosis in ICU: A French Multicenter Cohort Study Recruiting NCT03387696
15 Systemic Fungal Infections in Intensive Care Unit Patients Not yet recruiting NCT03292224

Search NIH Clinical Center for Mucormycosis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Isavuconazonium
Posaconazole
Sources

Genetic Tests for Mucormycosis

About this section
Sources

Anatomical Context for Mucormycosis

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Mucormycosis:

19
Brain, Sinuses, Lungs Of Immunocompromised People

MalaCards organs/tissues related to Mucormycosis:

41
Lung, Skin, Bone, Liver, Brain, Kidney, Myeloid
Sources

Publications for Mucormycosis

About this section

Articles related to Mucormycosis:

(show top 50) (show all 4026)
# Title Authors PMID Year
1
Mucormycosis experience through the eyes of the laboratory. 38
31364897 2019
2
A case report of cutaneous mucormycosis of the hand after minor trauma in a patient with acute myeloid leukaemia. 38
31360744 2019
3
Successful treatment of rhinoorbital mucormycosis due to Rhizopus arrhizus with liposomal amphotericin B, posaconazole and surgical debridement in a child with neuroblastoma. 38
31245270 2019
4
Mucormycosis diagnosed during induction chemotherapy in five pediatric patients with acute lymphoblastic leukemia. 38
31131954 2019
5
An unusual cause of bowel obstruction: Rhizopus Arrhizus diverticulitis. 38
31431881 2019
6
Mediastinal Mucormycosis: Case report, review of literature and treatment with continuous liposomal amphotericin B irrigation. 38
31044442 2019
7
Antifungal combinations in Mucorales: A microbiological perspective. 38
30830980 2019
8
Bowel infarction due to mucormycosis in an immunocompromised patient. 38
30929970 2019
9
Mucormycosis in South America: A review of 143 reported cases. 38
31192488 2019
10
Mucormycosis Presented with Facial Pain in a Renal Transplant Patient: A Case Report. 38
31405737 2019
11
Cardiac mucormycosis: a case report. 38
31436824 2019
12
Disseminated Pulmonary with Isolated Muscular Mucormycosis in an Acute Myeloid Leukemia Patient: A Case Report and Literature Review. 38
31417073 2019
13
[Advance study of rhinocerebralmucormycosis]. 38
31422642 2019
14
Estimated Burden of Fungal Infections in Namibia. 38
31426392 2019
15
Posaconazole Serum Drug Levels Associated with Pseudohyperaldosteronism. 38
31403165 2019
16
Serial monitoring of isavuconazole blood levels during prolonged antifungal therapy. 38
31119272 2019
17
Renal Mucormycosis: A Rare Cause of Urinary Tract Infection Leading to End-stage Renal Disease (ESRD). 38
30252109 2019
18
Intracranial fungal granuloma: a single-institute study of 90 cases over 18 years. 38
31370017 2019
19
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). 38
31393591 2019
20
Case series of cutaneous mucormycosis in the setting of Herpesviridae infection. 38
30633321 2019
21
Invasive mucormycosis during treatment for acute lymphoblastic leukaemia-successful management of two life-threatening diseases. 38
31410599 2019
22
Impairment of Th cell response in Card9 knockout mice with cutaneous mucormycosis caused by Rhizopus arrhizus. 38
31407820 2019
23
Saksenaea infection masquerading as a brain tumor in an immunocompetent child. 38
31373069 2019
24
Lichtheimia corymbifera Colonization Leading to Pulmonary Infection Can Be Prevented with Liposomal Amphotericin B in a New Murine Model. 38
31138564 2019
25
Role of Arf-like proteins (Arl1 and Arl2) of Mucor circinelloides in virulence and antifungal susceptibility. 38
31014992 2019
26
Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. 38
31427139 2019
27
[Fungal infections]. 38
31119309 2019
28
Mucormycosis due to Apophysomyces species complex- 25 years' experience at a tertiary care hospital in southern India. 38
31342074 2019
29
Mycotic Rhinitis and Sinusitis in Florida Horses. 38
30558508 2019
30
Posaconazole-Induced Hypertension Due to Inhibition of 11β-Hydroxylase and 11β-Hydroxysteroid Dehydrogenase 2. 38
31286100 2019
31
Allograft of Primary Cutaneous Mucormycosis in a Preterm Neonate: A Case Report. 38
31373557 2019
32
Isolated Intraventricular Chronic Mucormycosis in an Immunocompetent Infant: A Rare Case with Review of the Literature. 38
31279104 2019
33
Cranial nerve palsy: an unusual presentation of a fulminant fungal disease. 38
31305937 2019
34
Jejunal stricture due to mucormycosis. 38
31324130 2019
35
Mucormycosis of the Central Nervous System. 38
31288475 2019
36
Transcriptomic Analysis of Mucor irregularis Containing a Negative Single-Stranded RNA Mycovirus. 38
31346013 2019
37
Infection Due to Saksenaea vasiformis Following a Spider Bite. 38
30344020 2019
38
Necrotizing Mucormycosis of Wounds Following Combat Injuries, Natural Disasters, Burns, and Other Trauma. 38
31277364 2019
39
Gastrointestinal mucormycosis: An atypical cause of abdominal pain in an immunocompromised patient. 38
30126657 2019
40
Rhinocerebral mucormycosis with dissemination to pontine area in a diabetic patient: Treatment and management. 38
31360493 2019
41
Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges. 38
31399350 2019
42
A Guide to Investigating Suspected Outbreaks of Mucormycosis in Healthcare. 38
31344775 2019
43
In vitro interactions between isavuconazole and tacrolimus, cyclosporin A or sirolimus against Mucorales. 38
30934052 2019
44
The cost-effectiveness of isavuconazole compared to the standard of care in the treatment of patients with invasive fungal infection prior to differential pathogen diagnosis in the United Kingdom. 38
31262225 2019
45
Identification of Mucorales by Matrix-Assisted Laser Desorption Ionization Time-of-Flight Mass Spectrometry. 38
31269718 2019
46
Epidemiology and clinical outcomes of invasive mould infections in Indian intensive care units (FISF study). 38
30769292 2019
47
Posaconazole salvage therapy: The Posifi study. 38
30864238 2019
48
Concurrent cerebral aspergillosis and abdominal mucormycosis during ibrutinib therapy for chronic lymphocytic leukaemia. 38
30703527 2019
49
Evaluation of isavuconazole MIC strips for susceptibility testing of Aspergillus and Scedosporium species. 38
30124992 2019
50
Invasive sino-orbital fungal infections in immunocompetent patients: a clinico-pathological study. 38
30765886 2019
Sources

Variations for Mucormycosis

About this section
Sources

Expression for Mucormycosis

About this section
Search GEO for disease gene expression data for Mucormycosis.
Sources

Pathways for Mucormycosis

About this section

Pathways related to Mucormycosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Salmonella infection (KEGG) 37
11.32 IFNG CSF2
2
Glucocorticoid receptor regulatory network 1
11.28 IFNG CSF2
3
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 1
Show member pathways
 11.2 IFNG CSF2
4
Dendritic Cells Developmental Lineage Pathway 65
11.13 IFNG CSF2
5
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.01 IFNG CSF2
6
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 10.76 IFNG CSF2
7
Cytokines and Inflammatory Response 1
10.09 IFNG CSF2
Sources

GO Terms for Mucormycosis

About this section

Biological processes related to Mucormycosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.16 IFNG CSF2
2 cellular response to nerve growth factor stimulus GO:1990090 8.96 KIDINS220 HSPA5
3 positive regulation of interleukin-23 production GO:0032747 8.62 IFNG CSF2
Sources

Sources for Mucormycosis

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....